Infinity Pharma (NASDAQ:INFI) reported Q1 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $652 thousand versus the consensus estimate of $340 thousand.
Infinity Pharma (NASDAQ:INFI) reported Q1 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $652 thousand versus the consensus estimate of $340 thousand.